Cytotoxic chemotherapy has long been the backbone of treatment for colorectal cancer (CRC) in patients. In spite of advances in therapy, the 5-year survival rate is still unsatisfactory, mostly due to chemotherapy resistance in the therapy process. In our study, we demonstrated that the fat mass and obesity-associated (FTO) protein promotes CRC progression and increases chemotherapy resistance, thus, targeting FTO is a promising strategy for therapy CRC, which not only blocks tumor growth, but also reverses chemotherapy resistance.
![](/__local/1/C3/3C/2AFC44002B2C0D79F4FF3D8D35A_6BE6BCE2_60BF2.jpg)
https://doi.org/10.1002/ctm2.772